Pre-paid mail-back envelops for opioid prescriptions have reemerged as a potential REMS requirement, which may once again trigger questions about the idea’s efficacy and the US Food and Drug Administration’s role in drug disposal.
The agency is seeking comments on applying the idea to all immediate-release, extended-release and long-acting opioid formulations used in outpatient...




